Information Provided By: 
Fly News Breaks for October 29, 2018
SUPN
Oct 29, 2018 | 06:01 EDT
Mizuho analyst Irina Koffler views Supernus Pharmaceuticals' risk/reward as favorable into the Q4 Phase III adult attention-deficit/hyperactivity disorder read-out for SPN-812. The Phase IIb efficacy data for SPN-812 was similar to approved drugs, and the Phase III study design did not introduce any novel changes to a well-established blueprint for approval, Koffler tells investors in a research note. She reiterates a Buy rating on Supernus with a $61 price target.
News For SUPN From the Last 2 Days
There are no results for your query SUPN
